FR2814959A1 - Atomiser for pharmaceutical products based on antiinflammatory agents comprises pressurized container, dosing pouch and metering valve - Google Patents

Atomiser for pharmaceutical products based on antiinflammatory agents comprises pressurized container, dosing pouch and metering valve Download PDF

Info

Publication number
FR2814959A1
FR2814959A1 FR0100263A FR0100263A FR2814959A1 FR 2814959 A1 FR2814959 A1 FR 2814959A1 FR 0100263 A FR0100263 A FR 0100263A FR 0100263 A FR0100263 A FR 0100263A FR 2814959 A1 FR2814959 A1 FR 2814959A1
Authority
FR
France
Prior art keywords
nozzle
valve
pressurized container
dosing
spraying
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
FR0100263A
Other languages
French (fr)
Inventor
Jean Christophe Bertrand
Martine Dubois
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires Menarini France SA
Original Assignee
Laboratoires Menarini France SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0012881A external-priority patent/FR2814954B1/en
Application filed by Laboratoires Menarini France SA filed Critical Laboratoires Menarini France SA
Priority to FR0100263A priority Critical patent/FR2814959A1/en
Publication of FR2814959A1 publication Critical patent/FR2814959A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B65CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65DCONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D83/00Containers or packages with special means for dispensing contents
    • B65D83/14Containers or packages with special means for dispensing contents for delivery of liquid or semi-liquid contents by internal gaseous pressure, i.e. aerosol containers comprising propellant for a product delivered by a propellant
    • B65D83/44Valves specially adapted therefor; Regulating devices
    • B65D83/52Valves specially adapted therefor; Regulating devices for metering
    • B65D83/54Metering valves ; Metering valve assemblies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

Atomiser comprises a pressurized container with a plunger tube (18), an elastomer dosing pouch (9), and a metering valve (8). The product is discharged through a nozzle (2) with an outlet (1). The valve has an orifice (16) through which the liquid from the container, pressurized by the dosing pouch, which has a base seal (17), enters the valve. Atomiser comprises a pressurized container with a plunger tube (18), an elastomer dosing pouch (9), and a metering valve (8). The product is discharged through a nozzle (2) with an outlet (1). The valve has an orifice (16) through which the liquid from the container, pressurized by the dosing pouch, which has a base seal (17), enters the valve. The orifice also serves to return the product to the container when the nozzle pressure is released.

Description

<Desc/Clms Page number 1> <Desc / Clms Page number 1>

NOUVEAU DISPOSITIF DE PULVERISATION POUR FORMES PHARMACEUTIQUES A BASE D'AGENT ANTI-INFLAMMATOIRE ET LES FORMES AINSI REALISEES La présente invention se rapporte au domaine de la chimie thérapeutique et plus particulièrement au domaine de la formulation pharmaceutique.  NEW SPRAYING DEVICE FOR PHARMACEUTICAL FORMS BASED ON ANTI-INFLAMMATORY AGENT AND THE FORMS THUS PRODUCED The present invention relates to the field of therapeutic chemistry and more particularly to the field of pharmaceutical formulation.

Elle concerne plus spécifiquement des formes pharmaceutiques liquides contenant un agent anti-inflammatoire, susceptible d'être projetées par pulvérisation sur la zone ou la région nécessitant l'application d'un agent anti-inflammatoire. It relates more specifically to liquid pharmaceutical forms containing an anti-inflammatory agent, capable of being sprayed onto the area or region requiring the application of an anti-inflammatory agent.

L'invention concerne spécifiquement un dispositif de pulvérisation pour préparations pharmaceutiques, qui consiste à répartir une solution à base d'agent anti-inflammatoire dans des bidons propres à la pressurisation, à saturer l'atmosphère existant au-dessus de la phase liquide par injection d'un gaz inerte non miscible à l'eau et à un alcanol, à placer au sommet du bidon une valve obturatrice comportant un bouton poussoir actionnant ladite valve. The invention relates specifically to a spray device for pharmaceutical preparations, which consists in distributing a solution based on anti-inflammatory agent in cans suitable for pressurization, in saturating the atmosphere existing above the liquid phase by injection. of an inert gas immiscible with water and an alkanol, to be placed at the top of the container a shut-off valve comprising a push button actuating said valve.

L'application de produits anti-inflammatoires s'effectue en général sous forme d'une crème, d'un gel, d'un liniment ou d'une pommade sur la zone enflammée. The application of anti-inflammatory products is generally carried out in the form of a cream, gel, liniment or ointment on the inflamed area.

L'application de telles préparations ne nécessite pas de modalités particulières si ce n'est le massage de la région pour assurer un bon étalement de la composition et en outre pour en assurer la pénétration à travers l'épiderme. Cette pénétration nécessite en outre l'addition d'un promoteur qui facilite le passage de la préparation à travers l'épiderme. Sans cela, une fraction très faible de la préparation passe à travers la peau et il en résulte une perte considérable de préparation. The application of such preparations does not require any particular modalities except massaging the region to ensure good spreading of the composition and furthermore to ensure penetration thereof through the epidermis. This penetration also requires the addition of a promoter which facilitates the passage of the preparation through the epidermis. Without it, a very small fraction of the preparation passes through the skin and this results in a considerable loss of preparation.

L'étalement d'une pommade ou d'une crème sur une zone enflammée peut être douloureux en raison de la rubéfaction de cette zone et de la manipulation mécanique plus ou moins énergique rendue nécessaire. Spreading an ointment or cream on an inflamed area can be painful due to the reddening of this area and the more or less energetic mechanical manipulation made necessary.

C'est pourquoi il est apparu souhaitable de procéder différemment à l'administration, par voie topique, des préparations destinées à être appliquées sur des zones This is why it appeared desirable to proceed differently with the administration, by topical route, of the preparations intended to be applied to areas

<Desc/Clms Page number 2><Desc / Clms Page number 2>

articulaires ou tendineuses, douloureuses et/ou enflammées sans qu'il soit nécessaire d'avoir recours à des manipulations physiques.  joint or tendon painful and / or inflamed without the need for physical manipulation.

En conséquence il s'est avéré particulièrement intéressant de réaliser des compositions pressurisées à base d'agent anti-inflammatoire et de les pulvériser sur la zone à traiter à une pression suffisante pour que la préparation pulvérisée s'étale sur la totalité de la zone à traiter et pénètre au maximum dans le derme. Consequently, it has been found to be particularly advantageous to produce pressurized compositions based on anti-inflammatory agent and to spray them on the area to be treated at a pressure sufficient for the sprayed preparation to spread over the entire area to be treated. treat and penetrate as much as possible into the dermis.

L'agent anti-inflammatoire selon l'invention est un acide arylacétique et en particulier le Kétoprofène sous forme (R), sous forme (S) ou sous forme (RS). The anti-inflammatory agent according to the invention is an arylacetic acid and in particular Ketoprofen in form (R), in form (S) or in form (RS).

L'agent anti-inflammatoire peut être également sous forme de sel et notamment de sel de métal alcalin ou alcalinoterreux comme un sel de sodium, de potassium, de lithium, de magnésium ou de calcium. Il peut être également sous forme de sel de base organique comme une amine, un aminoalcool, un aminoacide basique ou un sel d'ammonium quaternaire. The anti-inflammatory agent can also be in the form of a salt and in particular of an alkali or alkaline earth metal salt such as a sodium, potassium, lithium, magnesium or calcium salt. It can also be in the form of an organic base salt such as an amine, an amino alcohol, a basic amino acid or a quaternary ammonium salt.

Parmi ceux-ci on citera tout particulièrement les sels de diethylamin, de diethylaminoéthanol, de triethanolamine, de N-méthyl glucamin, de trométhamine, de trométhamol, de lysine, d'arginine, de N-méthyl benzylamine, de pipéridino éthanol, de pyrolidino éthanol, de N-méthyl pipérazine ou bien encore de cétyl pyridinium. Among these, mention will be made most particularly of the salts of diethylamin, diethylaminoethanol, triethanolamine, N-methyl glucamin, tromethamine, tromethamol, lysine, arginine, N-methyl benzylamine, piperidino ethanol, pyrolidino ethanol, N-methyl piperazine or even cetyl pyridinium.

Les sels avec une base organique présentent l'avantage d'être plus solubles dans les solvants organiques que les sels avec une base minérale et peuvent ainsi être plus aisément dissous en milieu organique. On peut également réaliser des solutions plus concentrées. Salts with an organic base have the advantage of being more soluble in organic solvents than salts with an inorganic base and can thus be more easily dissolved in an organic medium. It is also possible to produce more concentrated solutions.

Le solvant organique utilisé pour disperser ou dissoudre le principe actif est un alcanol et de préférence un alcanol ayant de 1 à 6 atomes de carbone. On pourra citer à cet égard le méthanol, l'éthanol, le propanol, l'isopropanol, les n et i-butanols, le terbutanol, le néopentanol ou le n-hexanol. Ces alkanols peuvent être dilués par addition d'eau de manière à réaliser des véhicules hydroalcooliques comme de l'alcool éthylique à 50 % ou à 95 %, ou de l'isopropanol ou du terbutanol à 20 % d'eau. The organic solvent used to disperse or dissolve the active principle is an alkanol and preferably an alkanol having from 1 to 6 carbon atoms. Mention may be made in this regard of methanol, ethanol, propanol, isopropanol, n and i-butanols, terbutanol, neopentanol or n-hexanol. These alkanols can be diluted by adding water so as to produce hydroalcoholic vehicles such as 50% or 95% ethyl alcohol, or isopropanol or terbutanol at 20% water.

<Desc/Clms Page number 3> <Desc / Clms Page number 3>

Figure img00030001

Le soluté peut être avantageusement additionné d'un agent de pénétration comme par exemple le solketal, l'azone, le méthylal, le monocaprylate de propylèneglycol (Caprisol 90), l'octyl-2 dodecanol ou le 2-n-nonyl 1, 3-dioxolane. La proportion d'agent de pénétration varie de 3 à 8 % de la composition totale et d'une manière davantage préférée de 4 à 6 % en poids.
Figure img00030001

The solute can advantageously be added with a penetrating agent such as for example solketal, azone, methylal, propylene glycol monocaprylate (Caprisol 90), 2-octyl dodecanol or 2-n-nonyl 1, 3 -dioxolane. The proportion of penetrating agent varies from 3 to 8% of the total composition and more preferably from 4 to 6% by weight.

Le véhicule alcoolique est en outre additionné d'un agent épaississant comme par exemple un poly éthylène glycol et notamment un PEG 400 ou un PEG 600. The alcoholic vehicle is also added with a thickening agent such as for example a polyethylene glycol and in particular a PEG 400 or a PEG 600.

Le pH du véhicule est légèrement acide (valeur 4, 5-5). On l'ajuste aux alentours de 5,5 par addition de la quantité minimale d'hydroxyde de sodium, tout en respectant les zones de pH compatibles avec la stabilité du principe actif et la durabilité de la suspension, en fonction des caractéristiques chimiques des autres ingrédients. En particulier l'utilisation de sels de Kétoprofène très basiques nécessite l'ajustement du pH à l'aide d'acides minéraux ou organiques. The vehicle pH is slightly acidic (value 4, 5-5). It is adjusted to around 5.5 by adding the minimum quantity of sodium hydroxide, while respecting the pH zones compatible with the stability of the active principle and the durability of the suspension, depending on the chemical characteristics of the others. ingredients. In particular, the use of very basic Ketoprofen salts requires adjustment of the pH using mineral or organic acids.

Le soluté à disperser peut avantageusement être additionné d'un parfum comme un produit aromatisant ou odoriférant. On pourra citer à cet égard l'essence de roses, l'essence de neroli, l'essence de petit-grain, l'essence de lavande, l'essence de lavandin, l'essence de thym, l'essence d'eucalyptus ou l'essence d'ylang-ylang, ainsi que des produits synthétiques comme la vetivone, la damascone, l'irone ou les ionones. The solute to be dispersed can advantageously be added with a perfume such as a flavoring or odorant product. We can cite in this regard the essence of roses, the essence of neroli, the essence of petit-grain, the essence of lavender, the essence of lavandin, the essence of thyme, the essence of eucalyptus or the essence of ylang-ylang, as well as synthetic products like vetivone, damascone, irone or ionones.

Le produit aromatisant ou odoriférant est additionné en quantité de 0,05 à 1 % de la composition totale. Une quantité préférée s'échelonne de 0,1 à 0,6 %. The flavoring or fragrance product is added in an amount of 0.05 to 1% of the total composition. A preferred amount ranges from 0.1 to 0.6%.

L'angle de pulvérisation assuré par la valve du dispositif de pulvérisation varie entre 40 et 500. Il permet de couvrir à chaque projection une zone plus ou moins étalée. The spray angle provided by the valve of the spray device varies between 40 and 500. It makes it possible to cover a more or less spread out area with each spraying.

L'évaporation rapide du solvant organique assure un moindre écoulement de la préparation sur l'épiderme et une meilleure adhésion sur les zones traitées. The rapid evaporation of the organic solvent ensures less flow of the preparation on the epidermis and better adhesion on the treated areas.

La valve sert également de moyen de dosage. Une poussée sur le bouton-poussoir permet la délivrance d'un volume de solution variant de 0,2 à 0,8 ml et de préférence de 0,4 à 0,6 ml. Le volume projeté dépend de la pression gazeuse régnant dans le bidon pressurisé. La valve utilisée de préférence est celle commercialisée par la société Sofab. The valve also serves as a metering means. A push on the push-button allows the delivery of a volume of solution varying from 0.2 to 0.8 ml and preferably from 0.4 to 0.6 ml. The projected volume depends on the gas pressure prevailing in the pressurized container. The valve preferably used is the one sold by the company Sofab.

<Desc/Clms Page number 4> <Desc / Clms Page number 4>

La concentration en principe actif dans la solution alcanolique s'échelonne de 1 à 10 % et de préférence de 2 à 5 %. De cette façon, chaque poussée permet la délivrance de 0,02 g à 0,8 g de principe actif. The concentration of active ingredient in the alkanolic solution ranges from 1 to 10% and preferably from 2 to 5%. In this way, each push allows the delivery of 0.02 g to 0.8 g of active principle.

La pompe doseuse selon l'invention qui permet la pulvérisation comprend, outre la solution hydroalkanolique d'agent anti-inflammatoire, un corps plongeant dans le liquide à pulvériser, une poche doseuse surmontée d'un clapet de mesure, un corps de soutien de la poche doseuse, des coupelles symétriques en aluminium sur lesquelles reposent, symétriquement disposés, une partie obturatrice serrée contre la coupelle par un joint interne, ainsi que deux amortisseurs en élastomère, disposés de part et d'autre de l'axe de l'obturateur, et le corps du gicleur mobile dans le sens vertical maintenu en place par des ressorts, sur lequel vient se fixer la buse de pulvérisation. The dosing pump according to the invention which allows spraying comprises, in addition to the hydroalkanolic solution of anti-inflammatory agent, a body immersed in the liquid to be sprayed, a dosing bag surmounted by a measuring valve, a body for supporting the dosing pocket, symmetrical aluminum cups on which rest, symmetrically arranged, a shutter part tightened against the cup by an internal seal, as well as two elastomer dampers, arranged on either side of the axis of the shutter, and the body of the nozzle movable in the vertical direction held in place by springs, on which is fixed the spray nozzle.

La valve est terminée par un embout légèrement arrondi sur lequel vient s'emboîter la valve doseuse. The valve is terminated by a slightly rounded tip on which the metering valve fits.

Les bidons de remplissage sont remplis sous atmosphère d'un gaz inerte comme l'azote, l'hélium, l'argon, le protoxyde d'azote, le gaz carbonique ou un hydrocarbure. The filling cans are filled under an inert gas atmosphere such as nitrogen, helium, argon, nitrous oxide, carbon dioxide or a hydrocarbon.

La pression exercée sur la valve doseuse fait descendre la tige du gicleur en contact avec le clapet de mesure de sorte que le liquide sous pression dans le tube plongeur pénètre dans le gicleur et est évacué par la valve dès que la pression se relâche. The pressure exerted on the metering valve lowers the nozzle rod in contact with the measuring valve so that the liquid under pressure in the dip tube enters the nozzle and is evacuated by the valve as soon as the pressure is released.

Le gicleur est en copolymère acétal. Le tube plongeur est en polyéthylène. Le tube plongeur présente une longueur de 4 à 5 mm et un diamètre de 0,15 à 0,20 mm. The nozzle is made of acetal copolymer. The dip tube is made of polyethylene. The dip tube has a length of 4 to 5 mm and a diameter of 0.15 to 0.20 mm.

La figure 1 annexée montre une coupe du bidon pressurisé comportant la tige du gicleur (2), l'extrémité de la tige du gicleur (1), les deux amortisseurs symétriques (3) (3'), les supports de base de la tige du gicleur (4) encastrés dans le corps du gicleur (2) par un évidement (19) et reposant sur deux pivots (11) (11') montés sur un capot d'étanchéité (12). Ils sont assujettis au clapet de mesure (8) par deux ressorts (13) (13') fixés à leur extrémité inférieure sur un rebord (14) (14') du clapet. Le clapet (15) comporte en son centre un orifice (16) par lequel monte le liquide sous pression, contenu dans le bidon pressurisé (non figuré) par l'intermédiaire de la poche doseuse (9) en élastomère, fermée par un joint d'étanchéité (17) à sa base. Le tube plongeur Figure 1 attached shows a section of the pressurized container comprising the nozzle rod (2), the end of the nozzle rod (1), the two symmetrical dampers (3) (3 '), the base supports of the rod nozzle (4) embedded in the body of the nozzle (2) by a recess (19) and resting on two pivots (11) (11 ') mounted on a sealing cover (12). They are fixed to the measurement valve (8) by two springs (13) (13 ') fixed at their lower end on a flange (14) (14') of the valve. The valve (15) has in its center an orifice (16) through which the pressurized liquid rises, contained in the pressurized container (not shown) by means of the dosing bag (9) made of elastomer, closed by a seal d seal (17) at its base. The dip tube

<Desc/Clms Page number 5><Desc / Clms Page number 5>

(18) assure la montée du liquide (13) dans la poche doseuse (9) puis dans le corps du clapet (15).  (18) ensures the rise of the liquid (13) in the dosing bag (9) then in the body of the valve (15).

Après relâchement de la valve doseuse, le liquide redescend par le tube plongeur (18) dans le bidon pressurisé. After releasing the metering valve, the liquid descends through the dip tube (18) into the pressurized container.

Les exemples suivants illustrent l'invention sans toutefois la limiter. The following examples illustrate the invention without, however, limiting it.

EXEMPLE 1 Soluté de Kétoprofène On dissout 5 g de Kétoprofène dans 80 g d'éthanol à 95-96 %. On ajoute 30 g de poly éthylène glycol 400 (commercialisé sous la dénomination Lutrol E 400). On ajoute avec précaution quelques gouttes de solution d'hydroxyde de sodium à 30 %, à la solution acide (pH 4,7) pour obtenir un pH de 5,5. On complète la solution avec de l'eau purifiée à 200 g. La solution est alors introduite dans des flacons sous pression de 15 ml. On ferme le flacon avec le gicleur et on injecte de l'azote jusqu'à ce que la pression gazeuse à l'intérieur s'élève à 7 bars. On place alors la valve que l'on sertit sur l'embout du gicleur. EXAMPLE 1 Ketoprofen solution 5 g of Ketoprofen are dissolved in 80 g of 95-96% ethanol. 30 g of polyethylene glycol 400 (sold under the name Lutrol E 400) are added. Carefully add a few drops of 30% sodium hydroxide solution to the acid solution (pH 4.7) to obtain a pH of 5.5. The solution is made up with purified water to 200 g. The solution is then introduced into 15 ml pressure vials. The bottle is closed with the nozzle and nitrogen is injected until the gas pressure inside is 7 bars. Then place the valve that is crimped on the nozzle tip.

EXEMPLE 2 Soluté de Kétoprofène, sel de Trométhamine On dissout 6,65 g de sel de Trométhamine de Kétoprofène dans 80 g d'éthanol à 50 %. On ajoute 12 g de poly éthylène glycol 400 et on ajuste le pH du milieu à 5,5 par addition d'une solution d'acide chlorhydrique à 1 %. On complète la solution à 200 g avec de l'eau de roses. On répartit après homogénéisation la solution hydroalcoolique dans des flacons pressurisés de 15 ml. On obture le flacon par insertion du gicleur monté sur le tube plongeur. On injecte de l'azote jusqu'à ce que la pression interne s'élève à 7 bars. On dispose alors la valve que l'on sertit sur l'embout du gicleur. EXAMPLE 2 Ketoprofen solution, Tromethamine salt 6.65 g of Trethamine salt of Ketoprofen is dissolved in 80 g of 50% ethanol. 12 g of polyethylene glycol 400 are added and the pH of the medium is adjusted to 5.5 by addition of a 1% hydrochloric acid solution. The solution is made up to 200 g with rose water. The hydroalcoholic solution is distributed after homogenization in 15 ml pressurized bottles. The bottle is closed by inserting the nozzle mounted on the dip tube. Nitrogen is injected until the internal pressure rises to 7 bars. We then have the valve that is crimped on the nozzle tip.

EXEMPLE 111 Soluté de Kétoprofène avec agent pénétrant On prépare une solution prête à la pulvérisation, de formule : - Kétoprofène 2, 5 % - Lutrol E 400 10% - Huile essentielle de Lavandin 0, 1 %  EXAMPLE 111 Ketoprofen solution with penetrating agent A solution ready for spraying is prepared, of formula: - Ketoprofen 2.5% - Lutrol E 400 10% - Lavandin essential oil 0.1%

<Desc/Clms Page number 6> <Desc / Clms Page number 6>

Figure img00060001

- Solkétal 5% - Alcool 95-96 % 40 % - Eau purifiée qsp 100% - Hydroxyde de sodium à 30 % qsp pH 5, 5 La solution est répartie après homogénéisation dans des flacons pressurisés de 15 ml.
Figure img00060001

- Solkétal 5% - Alcohol 95-96% 40% - Purified water qs 100% - Sodium hydroxide at 30% qs pH 5, 5 The solution is distributed after homogenization in pressurized bottles of 15 ml.

On ferme le flacon avec le gicleur et on injecte de l'azote jusqu'à ce que la pression gazeuse à l'intérieur s'élève à 7 bars. On place alors la valve que l'on sertit sur l'embout du gicleur. The bottle is closed with the nozzle and nitrogen is injected until the gas pressure inside is 7 bars. Then place the valve that is crimped on the nozzle tip.

Les compositions selon l'invention trouvent une utilisation dans le traitement des phénomènes douloureux ou inflammatoires de l'appareil locomoteur notamment en cas de tendinites ou dans la traumatologie.The compositions according to the invention find use in the treatment of painful or inflammatory phenomena of the musculoskeletal system, in particular in the case of tendonitis or in trauma.

Claims (8)

REVENDICATIONS 1. Dispositif de pulvérisation des compositions pharmaceutiques à action anti- inflammatoire, caractérisé en ce qu'il contient, outre une solution hydroalkanolique d'agent anti-inflammatoire, un bidon pressurisé comprenant un corps plongeant dans le liquide à pulvériser, une poche doseuse surmontée d'un clapet de mesure, un corps de soutien de la poche doseuse, des coupelles symétriques en aluminium sur lesquelles reposent, disposés symétriquement, un moyen d'obturation serré contre la coupelle par un joint interne ainsi que deux amortisseurs en élastomère, disposés de part et d'autre de l'axe de l'obturateur et le corps du gicleur, mobile dans le sens vertical, maintenu en place par des ressorts, sur lequel vient se fixer la buse de pulvérisation. CLAIMS 1. Device for spraying pharmaceutical compositions with anti-inflammatory action, characterized in that it contains, in addition to a hydroalkanolic solution of anti-inflammatory agent, a pressurized container comprising a body immersed in the liquid to be sprayed, a dosing bag surmounted by a measuring valve, a support body for the dosing pocket, symmetrical aluminum cups on which rest, arranged symmetrically, a sealing means tightened against the cup by an internal seal as well as two elastomer dampers, arranged on either side of the shutter axis and the body of the nozzle, movable in the vertical direction, held in place by springs, on which is fixed the spray nozzle. 2. Dispositif de pulvérisation de compositions pharmaceutiques selon la revendication 1, caractérisé en ce qu'il est formé d'un bidon pressurisé comportant la tige d'un gicleur (2), l'extrémité de la tige du gicleur (1), deux amortisseurs symétriques (3) (3'), des supports de base de la tige du gicleur (4) encastrés dans le corps du gicleur (2) par un évidemment (19) et reposant sur deux pivots (11) (11') montés sur un capot d'étanchéité (12), assujettis au clapet de mesure (8) par deux ressorts (13) (13') fixés à leur extrémité inférieure sur un rebord (14) (14') du corps du clapet (15), celui-ci comportant en son milieu un orifice (16) par lequel monte le liquide sous pression contenu dans le bidon pressurisé par l'intermédiaire d'une poche doseuse (9) en élastomère fermée par un joint d'étanchéité (17) à sa base, et qui comporte un tube plongeur (18) qui assure la montée du liquide (13) dans la poche doseuse (9) puis dans le corps du clapet (15). 2. Device for spraying pharmaceutical compositions according to claim 1, characterized in that it is formed from a pressurized container comprising the rod of a nozzle (2), the end of the rod of the nozzle (1), two symmetrical dampers (3) (3 '), basic supports of the nozzle rod (4) embedded in the body of the nozzle (2) by a recess (19) and resting on two pivots (11) (11') mounted on a sealing cover (12), secured to the measurement valve (8) by two springs (13) (13 ') fixed at their lower end on a flange (14) (14') of the valve body (15) , the latter comprising in its middle an orifice (16) through which the pressurized liquid contained in the pressurized container rises by means of an elastomer dosing bag (9) closed by a seal (17) at its base, and which comprises a dip tube (18) which ensures the rise of the liquid (13) in the dosing bag (9) then in the body of the valve (15). 3. Dispositif de pulvérisation selon la revendication 1 ou la revendication 2, caractérisé en ce qu'en relâchant la pression sur le gicleur assujetti à l'extrémité de la tige du gicleur (2), le liquide redescend par l'intermédiaire de l'orifice (16) du tube plongeur (18), dans le bidon pressurisé et permet ainsi une nouvelle utilisation. 3. Spraying device according to claim 1 or claim 2, characterized in that by releasing the pressure on the nozzle subject to the end of the nozzle rod (2), the liquid descends through the orifice (16) of the dip tube (18) in the pressurized container and thus allows a new use. <Desc/Clms Page number 8> <Desc / Clms Page number 8> 4. Dispositif de pulvérisation selon l'une des revendications 1 à 3, dans lequel la pression interne est assurée par injection d'un gaz inerte. 4. Spray device according to one of claims 1 to 3, wherein the internal pressure is provided by injection of an inert gas. 5. Dispositif de pulvérisation selon l'une des revendications 1 à 4, dans lequel le gaz inerte est de l'azote, du protoxyde d'azote, du gaz carbonique ou un hydrocarbure. 5. Spray device according to one of claims 1 to 4, wherein the inert gas is nitrogen, nitrous oxide, carbon dioxide or a hydrocarbon. 6. Dispositif de pulvérisation selon l'une des revendications 1 à 5, dans lequel le gaz inerte est présent sous une pression réglée de préférence à 7 bars. 6. Spray device according to one of claims 1 to 5, in which the inert gas is present under a pressure preferably set at 7 bars. 7. Dispositif de pulvérisation selon l'une des revendications 1 à 6 caractérisé en ce que la valve utilisée permet la délivrance d'un volume de solution variant de 0,2 ml à 0,8 ml soit 0,02 g à 0,8 g de principe actif en fonction de la pression gazeuse régnant dans le bidon pressurisé. 7. Spray device according to one of claims 1 to 6 characterized in that the valve used allows the delivery of a volume of solution varying from 0.2 ml to 0.8 ml or 0.02 g to 0.8 g of active principle as a function of the gas pressure prevailing in the pressurized container. 8. Dispositif de pulvérisation selon l'une des revendications 1 à 7, dans lequel l'angle de pulvérisation assuré par la valve obturatrice varie entre 40 et 50 . 8. Spraying device according to one of claims 1 to 7, in which the spraying angle provided by the shutter valve varies between 40 and 50.
FR0100263A 2000-10-09 2001-01-10 Atomiser for pharmaceutical products based on antiinflammatory agents comprises pressurized container, dosing pouch and metering valve Withdrawn FR2814959A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR0100263A FR2814959A1 (en) 2000-10-09 2001-01-10 Atomiser for pharmaceutical products based on antiinflammatory agents comprises pressurized container, dosing pouch and metering valve

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0012881A FR2814954B1 (en) 2000-10-09 2000-10-09 NOVEL PHARMACEUTICAL COMPOSITIONS IN THE SPRAY FORM AND THE FORMS THUS PRODUCED
FR0100263A FR2814959A1 (en) 2000-10-09 2001-01-10 Atomiser for pharmaceutical products based on antiinflammatory agents comprises pressurized container, dosing pouch and metering valve

Publications (1)

Publication Number Publication Date
FR2814959A1 true FR2814959A1 (en) 2002-04-12

Family

ID=26212677

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0100263A Withdrawn FR2814959A1 (en) 2000-10-09 2001-01-10 Atomiser for pharmaceutical products based on antiinflammatory agents comprises pressurized container, dosing pouch and metering valve

Country Status (1)

Country Link
FR (1) FR2814959A1 (en)

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8343945B2 (en) 2007-12-07 2013-01-01 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US8362091B2 (en) 2003-08-04 2013-01-29 Foamix Ltd. Foamable vehicle and pharmaceutical compositions thereof
US8435498B2 (en) 2002-10-25 2013-05-07 Foamix Ltd. Penetrating pharmaceutical foam
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US8486375B2 (en) 2003-04-28 2013-07-16 Foamix Ltd. Foamable compositions
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
US8518376B2 (en) 2007-12-07 2013-08-27 Foamix Ltd. Oil-based foamable carriers and formulations
US8518378B2 (en) 2003-08-04 2013-08-27 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US8617100B2 (en) 2007-09-04 2013-12-31 Foamix Ltd. Device for delivery of a foamable composition
US8618081B2 (en) 2009-10-02 2013-12-31 Foamix Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US8709385B2 (en) 2008-01-14 2014-04-29 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
US8722021B2 (en) 2002-10-25 2014-05-13 Foamix Ltd. Foamable carriers
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US8795635B2 (en) 2006-11-14 2014-08-05 Foamix Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US8978936B2 (en) 2010-07-12 2015-03-17 Foamix Pharmaceuticals Ltd. Apparatus and method for releasing a unit dose of content from a container
US9072667B2 (en) 2009-07-29 2015-07-07 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US9167813B2 (en) 2009-07-29 2015-10-27 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9320705B2 (en) 2002-10-25 2016-04-26 Foamix Pharmaceuticals Ltd. Sensation modifying topical composition foam
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
US9539208B2 (en) 2002-10-25 2017-01-10 Foamix Pharmaceuticals Ltd. Foam prepared from nanoemulsions and uses
US9622947B2 (en) 2002-10-25 2017-04-18 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US9884017B2 (en) 2009-04-28 2018-02-06 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2076684A5 (en) * 1970-01-23 1971-10-15 Ydev Sa

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2076684A5 (en) * 1970-01-23 1971-10-15 Ydev Sa

Cited By (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
US9492412B2 (en) 2002-10-25 2016-11-15 Foamix Pharmaceuticals Ltd. Penetrating pharmaceutical foam
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US9539208B2 (en) 2002-10-25 2017-01-10 Foamix Pharmaceuticals Ltd. Foam prepared from nanoemulsions and uses
US11033491B2 (en) 2002-10-25 2021-06-15 Vyne Therapeutics Inc. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9713643B2 (en) 2002-10-25 2017-07-25 Foamix Pharmaceuticals Ltd. Foamable carriers
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US9622947B2 (en) 2002-10-25 2017-04-18 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US8435498B2 (en) 2002-10-25 2013-05-07 Foamix Ltd. Penetrating pharmaceutical foam
US9320705B2 (en) 2002-10-25 2016-04-26 Foamix Pharmaceuticals Ltd. Sensation modifying topical composition foam
US10322085B2 (en) 2002-10-25 2019-06-18 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US8722021B2 (en) 2002-10-25 2014-05-13 Foamix Ltd. Foamable carriers
US8741265B2 (en) 2002-10-25 2014-06-03 Foamix Ltd. Penetrating pharmaceutical foam
US8840869B2 (en) 2002-10-25 2014-09-23 Foamix Ltd. Body cavity foams
US10821077B2 (en) 2002-10-25 2020-11-03 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US8486375B2 (en) 2003-04-28 2013-07-16 Foamix Ltd. Foamable compositions
US8703105B2 (en) 2003-08-04 2014-04-22 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US9636405B2 (en) 2003-08-04 2017-05-02 Foamix Pharmaceuticals Ltd. Foamable vehicle and pharmaceutical compositions thereof
US8518378B2 (en) 2003-08-04 2013-08-27 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US9101662B2 (en) 2003-08-04 2015-08-11 Foamix Pharmaceuticals Ltd. Compositions with modulating agents
US9050253B2 (en) 2003-08-04 2015-06-09 Foamix Pharmaceuticals Ltd. Oleaginous pharmaceutical and cosmetic foam
US8362091B2 (en) 2003-08-04 2013-01-29 Foamix Ltd. Foamable vehicle and pharmaceutical compositions thereof
US8795635B2 (en) 2006-11-14 2014-08-05 Foamix Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US9682021B2 (en) 2006-11-14 2017-06-20 Foamix Pharmaceuticals Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US10369102B2 (en) 2007-08-07 2019-08-06 Foamix Pharmaceuticals Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US9662298B2 (en) 2007-08-07 2017-05-30 Foamix Pharmaceuticals Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US11103454B2 (en) 2007-08-07 2021-08-31 Vyne Therapeutics Inc. Wax foamable vehicle and pharmaceutical compositions thereof
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US8617100B2 (en) 2007-09-04 2013-12-31 Foamix Ltd. Device for delivery of a foamable composition
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
US11433025B2 (en) 2007-12-07 2022-09-06 Vyne Therapeutics Inc. Oil foamable carriers and formulations
US9549898B2 (en) 2007-12-07 2017-01-24 Foamix Pharmaceuticals Ltd. Oil and liquid silicone foamable carriers and formulations
US9795564B2 (en) 2007-12-07 2017-10-24 Foamix Pharmaceuticals Ltd. Oil-based foamable carriers and formulations
US8343945B2 (en) 2007-12-07 2013-01-01 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US8900553B2 (en) 2007-12-07 2014-12-02 Foamix Pharmaceuticals Ltd. Oil and liquid silicone foamable carriers and formulations
US9161916B2 (en) 2007-12-07 2015-10-20 Foamix Pharmaceuticals Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US8518376B2 (en) 2007-12-07 2013-08-27 Foamix Ltd. Oil-based foamable carriers and formulations
US8709385B2 (en) 2008-01-14 2014-04-29 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
US9884017B2 (en) 2009-04-28 2018-02-06 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10213384B2 (en) 2009-04-28 2019-02-26 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10363216B2 (en) 2009-04-28 2019-07-30 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10588858B2 (en) 2009-04-28 2020-03-17 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10350166B2 (en) 2009-07-29 2019-07-16 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US9572775B2 (en) 2009-07-29 2017-02-21 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US11219631B2 (en) 2009-07-29 2022-01-11 Vyne Pharmaceuticals Inc. Foamable compositions, breakable foams and their uses
US9072667B2 (en) 2009-07-29 2015-07-07 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US10092588B2 (en) 2009-07-29 2018-10-09 Foamix Pharmaceuticals Ltd. Foamable compositions, breakable foams and their uses
US9167813B2 (en) 2009-07-29 2015-10-27 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US8992896B2 (en) 2009-10-02 2015-03-31 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10946101B2 (en) 2009-10-02 2021-03-16 Vyne Therapeutics Inc. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US10137200B2 (en) 2009-10-02 2018-11-27 Foamix Pharmaceuticals Ltd. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US10238746B2 (en) 2009-10-02 2019-03-26 Foamix Pharmaceuticals Ltd Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US10265404B2 (en) 2009-10-02 2019-04-23 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US8618081B2 (en) 2009-10-02 2013-12-31 Foamix Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US10322186B2 (en) 2009-10-02 2019-06-18 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US9675700B2 (en) 2009-10-02 2017-06-13 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10086080B2 (en) 2009-10-02 2018-10-02 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US10029013B2 (en) 2009-10-02 2018-07-24 Foamix Pharmaceuticals Ltd. Surfactant-free, water-free formable composition and breakable foams and their uses
US10463742B2 (en) 2009-10-02 2019-11-05 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10517882B2 (en) 2009-10-02 2019-12-31 Foamix Pharmaceuticals Ltd. Method for healing of an infected acne lesion without scarring
US8865139B1 (en) 2009-10-02 2014-10-21 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10610599B2 (en) 2009-10-02 2020-04-07 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10821187B2 (en) 2009-10-02 2020-11-03 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US8945516B2 (en) 2009-10-02 2015-02-03 Foamix Pharmaceuticals Ltd. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US10835613B2 (en) 2009-10-02 2020-11-17 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US8871184B2 (en) 2009-10-02 2014-10-28 Foamix Ltd. Topical tetracycline compositions
US10213512B2 (en) 2009-10-02 2019-02-26 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10967063B2 (en) 2009-10-02 2021-04-06 Vyne Therapeutics Inc. Surfactant-free, water-free formable composition and breakable foams and their uses
US8978936B2 (en) 2010-07-12 2015-03-17 Foamix Pharmaceuticals Ltd. Apparatus and method for releasing a unit dose of content from a container
US9463919B2 (en) 2010-07-12 2016-10-11 Foamix Pharmaceuticals Ltd. Apparatus and method for releasing a unit dose of content from a container
US10849847B2 (en) 2016-09-08 2020-12-01 Foamix Pharamaceuticals Ltd. Compositions and methods for treating rosacea and acne
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
US11324691B2 (en) 2016-09-08 2022-05-10 Journey Medical Corporation Compositions and methods for treating rosacea and acne

Similar Documents

Publication Publication Date Title
FR2814959A1 (en) Atomiser for pharmaceutical products based on antiinflammatory agents comprises pressurized container, dosing pouch and metering valve
US3304230A (en) Liquid aerosol propellant solutions of fatty acid salts of physiologically active amines
CA2857889C (en) Oleaginous pharmaceutical and cosmetic foam
KR101141220B1 (en) Foamable pharmaceutical compositions and methods for treating a disorder
JP5829217B2 (en) High penetrating terbinafine formulation
EP0478456B1 (en) Antifungal composition in dry aerosol form
FR2533826A1 (en) Compsn. for nasal admin. contg. calcitonin
LU84468A1 (en) HIGH-SOLUBILITY MEDICINES AND PROCESS FOR OBTAINING THEM
JPS6313965B2 (en)
FR2675382A1 (en) PARTICLES OF BIOLOGICALLY ACTIVE SUBSTANCES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
JPH0778019B2 (en) Foamed anti-inflammatory analgesic preparation
FR2959936A1 (en) NASAL COMPOSITION WITH A SYSTEMIC VIEW BASED ON COCOYL PROLINE OR AT LEAST ONE OF ITS COMPONENTS
EP0586295A1 (en) Quick-foaming, soap-free liquid compositions containing lower hydrocarbons and distributed from a pressurized gas container
US3875301A (en) Useful tetraalkyl diamides in the treatment of poison ivy
EP1195158B1 (en) Sprayable pharmaceutical compositions containing ketoprofen
JPWO2002083321A1 (en) Aerosol products
JP6018438B2 (en) Dripping aerosol products
JP5095239B2 (en) Aerosol composition for gel spray
JP4856868B2 (en) Aerosol composition
FR3039991A1 (en) ANTI-COLOR COMPOSITION COMPRISING A SALICYLIC ACID DERIVATIVE
JP3498041B2 (en) Nasal formulation containing pralmorelin
FR2647344A1 (en) Aerosol foam for rectal use
JPH11349933A (en) Aerosol product
FR2616065A1 (en) Quaternary ammonium-based pharmaceutical aerosol
BE897904A (en) NEW CALCITONIN-BASED GALENIC COMPOSITIONS

Legal Events

Date Code Title Description
ST Notification of lapse